Experts are rapidly examining retatrutide, a promising treatment developed by Eli Lilly, as a potential advance in physique loss . Different than many existing approaches, retatrutide is a twin-action agonist targeting equally GLP-1 and GIP, substances that impact satiety and glucose control . I